L C Price
Overview
Explore the profile of L C Price including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rowley J, Mahony M, Hines H, Myers S, Price L, Shea G, et al.
Zootaxa
. 2021 Nov;
5071(1):1-41.
PMID: 34810683
The bleating tree frog (Litoria dentata) is one of the more prominent pelodryadid frogs of eastern Australia by virtue of its extremely loud, piercing, male advertisement call. A member of...
2.
Wort S, Arachchillage D, McCabe C, Price L
Respir Med Res
. 2020 Sep;
78:100781.
PMID: 32889497
No abstract available.
3.
Vieillard-Baron A, Price L, Matthay M
Intensive Care Med
. 2013 Aug;
39(10):1836-8.
PMID: 23907498
No abstract available.
4.
Montani D, Price L, Girerd B, Chinet T, LACOMBE P, Simonneau G, et al.
Eur Respir Rev
. 2010 Oct;
18(111):42-6.
PMID: 20956122
A 29-yr-old patient with hereditary haemorrhagic telangiectasia was referred to the present authors' centre with progressive exertional dyspnoea. Pulmonary arterial hypertension (PAH) was suspected on Doppler echocardiography and confirmed by...
5.
Price L, Montani D, Tcherakian C, Dorfmuller P, Souza R, Gambaryan N, et al.
Eur Respir J
. 2010 Aug;
37(4):813-22.
PMID: 20693255
Pulmonary arterial hypertension (PAH) is associated with dysregulated bone morphogenetic protein receptor (BMPR)-II signaling and pulmonary vascular inflammation. We evaluated the effects of dexamethasone on monocrotaline (MCT)-induced PAH in rats...
6.
Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price L, et al.
Eur Respir J
. 2009 Nov;
35(6):1286-93.
PMID: 19897557
Acute right ventricular failure in the setting of pulmonary arterial hypertension (PAH) often requires hospitalisation in intensive care units (ICU) to manage the subsequent low cardiac output and its consequences....
7.
Price L, Montani D, Jais X, Dick J, Simonneau G, Sitbon O, et al.
Eur Respir J
. 2009 Nov;
35(6):1294-302.
PMID: 19897552
The anaesthetic management and follow-up of well-characterised patients with pulmonary arterial hypertension presenting for noncardiothoracic nonobstetric surgery has rarely been described. The details of consecutive patients and perioperative complications during...
8.
Montani D, Jais X, Price L, Achouh L, Degano B, Mercier O, et al.
Eur Respir J
. 2009 Jun;
34(6):1348-56.
PMID: 19541723
Pulmonary veno-occlusive disease (PVOD) carries a poor prognosis and lung transplantation is the only curative treatment. In PVOD, epoprostenol therapy is controversial, as this condition may be refractory to specific...
9.
Montani D, Price L, Dorfmuller P, Achouh L, Jais X, Yaici A, et al.
Eur Respir J
. 2009 Jan;
33(1):189-200.
PMID: 19118230
Pulmonary veno-occlusive disease (PVOD) is currently classified as a subgroup of pulmonary arterial hypertension (PAH) and accounts for 5-10% of cases initially considered to be idiopathic PAH. PVOD has been...
10.
Price L, Forrest P, Sodhi V, ADAMSON D, Nelson-Piercy C, Lucey M, et al.
Br J Anaesth
. 2007 Jul;
99(4):552-5.
PMID: 17660458
We report the successful use of vasopressin in the management of hypotension in association with severe right ventricular (RV) failure in two patients with advanced idiopathic pulmonary arterial hypertension. Both...